Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Targeted therapies showing great promise against colorectal cancer

04.04.2006


Results from a Phase III study of a new drug show promise for patients with colorectal cancer that has spread to other parts of the body, according to a study presented today during the 97th Annual Meeting of the American Association for Cancer Research.

Investigators have shown that panitumumab improves progression-free survival in patients with metastatic colorectal cancer (mCRC) who had failed standard chemotherapy. In the randomized trial of 463 patients, those who received panitumumab with best supportive care every two weeks (231 pts) showed a 46 percent decrease in the rate of tumor progression or death versus those who received only best supportive care (232 pts). At week 24, approximately four times as many pantimumab patients were alive and progression-free versus those on best-supportive care (18 percent versus five percent). Twice as many panitumumab patients were alive and progression-free at week 32 (10 percent versus four percent).

Study investigators also reported that panitumumab significantly improved disease control. In patients who responded, the median duration of response was 17 weeks. Extended follow-up also revealed that even after 32 weeks, a larger percentage of patients in the panitumumab with best supportive care group were alive without progression than in the group assigned to best supportive care alone.



"We are encouraged by these results, particularly that panitumumab was well-tolerated in patients with metastatic colorectal cancer, with very few major adverse reactions," said Marc Peeters, M.D., Ph.D., coordinator of the Digestive Oncology Unit, from Ghent University Hospital in Belgium.

Recently, researchers have begun to focus their efforts on developing cancer therapies that are not only effective, but also are easier on the body than current therapies. Using newer therapies that are derived from human protein sequences, investigators are finding that the body is less likely to develop side effects from these drug,s such as allergic reactions.

Panitumumab is the first fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr), a protein that plays an important role in cancer cell signaling. EGFr activates when naturally occurring proteins in the body, such as epidermal growth factor (EGF), bind to it and trigger signals to encourage cell growth. Panitumumab binds to EGFr, preventing the natural protein from binding to it and interfering with the signals that would otherwise stimulate growth of the cancer cell and allow it to survive.

"Studies involving the use of panitumumab alone and in combination with other therapies for various cancers may confirm that the use of human monoclonal antibodies is a great step forward to effectively treat cancer," said Dr. Peeters.

The most common side effect was rash, and other lesser side effects included fatigue, nausea and diarrhea. No anti-drug antibody formation was observed.

*Abstract No. CP-1: A Phase 3, Multicenter, Randomized Controlled Trial (RCT) of Panitumumab Plus Best Supportive Care (BSC) vs. BSC Alone in Patients (pts) with Metastatic Colorectal Cancer (mCRC)

Warren Froelich | EurekAlert!
Further information:
http://www.aacr.org

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>